2022 (Accepted for publication)
Riobo Aboy, P., Liddell, K., Jordan, M., Liddicoat, J. and Crespo, C., 2022 (Accepted for publication). European Patent Protection for Medical Uses of Known Products and Drug Repurposing Nature Biotechnology,
Doi: 10.1038/s41587-022-01269-3
2021 (Accepted for publication)
Liddicoat, J., Liddell, K. and Fritz, Z., 2021 (Accepted for publication). Reconsidering Repositioning Incentives: An Empirical Legal Analysis of Market Protection for New Therapeutic Indications European Pharmaceutical Law Review,
Liddicoat, J., Liddell, K., Aboy, M. and Wested, J., 2021 (Accepted for publication). Has the EU incentive for drug repositioning been effective? An empirical analysis of the “+1” regulatory exclusivity IIC International Review of Intellectual Property and Competition Law,
Jordan, M., Liddicoat, J. and Liddell, K., 2021 (Accepted for publication). An Empirical Study of Large, Human Biobanks: Intellectual Property Policies and Financial Conditions for Access Journal of Law and the Biosciences,
Riobo Aboy, P., Liddell, K., Liddicoat, J., Crespo, C. and Jordan, M., 2021 (Accepted for publication). Mapping the European Patent Landscape for Medical Uses of Known Products Nature Biotechnology,
2021
Liddicoat, J. and Wested, J., 2021. Repositioning for rare diseases – too much, too little or just right? Nordic Intellectual Property Law Review,
Liddicoat, J. and Parish, J., 2021. Ironing out the wrinkles: reforms to Crown use and compulsory licensing to help prepare the Patents Act 1977 for the next health crises Intellectual Property Quarterly, v. 4
2020 (Accepted for publication)
Aboy, M., Crespo, C., Liddell, K., Davey, N., Liddicoat, J. and Minssen, T., 2020 (Accepted for publication). One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections? Nature Biotechnology,
2020
Liddicoat, J., Liddell, K., McCarthy, AH., Hogarth, S., Aboy, M., Nicol, D., Patton, S. and Hopkins, MM., 2020. Reply to C.D. Richter. European Journal of Human Genetics,
Doi: http://doi.org/10.1038/s41431-020-0588-x
Liddicoat, J., Liddell, K., McCarthy, A., Hogarth, S., Aboy, M., Nicol, D., Patton, S. and Hopkins, MM., 2020. Reply to C.D. Richter European Journal of Human Genetics,
2019 (Accepted for publication)
Liddicoat, J., Liddell, K., McCarthy, A., Hogarth, S., Nicol, D., Patton, S. and Hopkins, M., 2019 (Accepted for publication). Continental drift? Do European clinical genetic testing laboratories have a patent problem? European Journal of Human Genetics,
Liddicoat, J., Liddell, K. and Aboy, M., 2019 (Accepted for publication). The Effects of Myriad and Mayo on Molecular Test Development in the US and Europe: Interviews from the Frontline Vanderbilt Journal of Entertainment and Technology Law, v. 22
Doi: http://doi.org/10.2139/ssrn.3381553
2019
Liddicoat, J. and de Werra, J., 2019. When can exclusive licensees initiate patent infringement proceedings?—Lessons for global IP licensing transactions from two recent UK cases Journal of Intellectual Property Law & Practice, v. 14
Doi: http://doi.org/10.1093/jiplp/jpy159
Nicol, D., Dreyfuss, RC., Gold, ER., Li, W., Liddicoat, J. and Van Overwalle, G., 2019. International Divergence in Gene Patenting. Annu Rev Genomics Hum Genet, v. 20
Doi: http://doi.org/10.1146/annurev-genom-083118-015112
Aboy, M., Liddell, K., Crespo, C., Cohen, IG., Liddicoat, J., Gerke, S. and Minssen, T., 2019. How does emerging patent case law in the US and Europe affect precision medicine? Nat Biotechnol, v. 37
Doi: http://doi.org/10.1038/s41587-019-0265-1
Aboy, M., Crespo, C., Liddell, K., Minssen, T. and Liddicoat, J., 2019. Mayo's impact on patent applications related to biotechnology, diagnostics and personalized medicine. Nat Biotechnol, v. 37
Doi: http://doi.org/10.1038/s41587-019-0111-5
2018 (Accepted for publication)
Powles, J. and Liddicoat, JE., 2018 (Accepted for publication). United Kingdom Patent Decisions 2017 IIC International Review of Intellectual Property and Competition Law,
2018
Aboy, M., Crespo, C., Liddell, K., Liddicoat, J. and Jordan, M., 2018. Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts? Nat Biotechnol, v. 36
Doi: http://doi.org/10.1038/nbt.4308
Liddicoat, JE., 2018. Divided Performance of Patented Methods in Australia: A Call to Codify Procured Infringement University of New South Wales Law Journal, v. 41
2017
Liddicoat, J., 2017. Standing on the Edge – What Type of “Exclusive Licensees” Should be Able to Initiate Patent Infringement Actions? IIC - International Review of Intellectual Property and Competition Law, v. 48
Doi: http://doi.org/10.1007/s40319-017-0620-z
Aboy, M., Liddicoat, J., Liddell, K., Jordan, M. and Crespo, C., 2017. After Myriad, what makes a gene patent claim 'markedly different' from nature? Nature Biotechnology, v. 35
Doi: http://doi.org/10.1038/nbt.3953
Nicol, D., Eckstein, L., Morrison, M., Sherkow, JS., Otlowski, M., Whitton, T., Bubela, T., Burdon, KP., Chalmers, D., Chan, S., Charlesworth, J., Critchley, C., Crossley, M., de Lacey, S., Dickinson, JL., Hewitt, AW., Kamens, J., Kato, K., Kleiderman, E., Kodama, S., Liddicoat, J., Mackey, DA., Newson, AJ., Nielsen, J., Wagner, JK. and McWhirter, RE., 2017. Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. Genome Medicine, v. 9
Doi: http://doi.org/10.1186/s13073-017-0475-4
Nielsen, JL. and Liddicoat, JE., 2017. The Multiple Dimensions of Intellectual Property Infringement in the 3D Printing Era Australian Intellectual Property Journal,
2016
Liddicoat, JE., Nielsen, JL. and Nicol, D., 2016. Three Dimensions of Patent Infringement: Liability for Creation and Distribution of CAD Files Australian Intellectual Property Journal,
Christie, AF., Dent, C. and Liddicoat, JE., 2016. The Examination Effect: A Comparison of the Outcome of Patent Examination in the US, Europe and Australia John Marshall Review of Intellectual Property Law, v. 16
Aboy, M., Liddell, K., Liddicoat, J. and Crespo, C., 2016. $\textit{Myriad's}$ impact on gene patents Nature Biotechnology, v. 34
Doi: http://doi.org/10.1038/nbt.3719
Nicol, D., Bubela, T., Chalmers, D., Charbonneau, J., Critchley, C., Dickinson, J., Fleming, J., Hewitt, AW., Kaye, J., Liddicoat, J., McWhirter, R., Otlowski, M., Ries, NM., Skene, L., Stewart, C., Wagner, J. and Zeps, N., 2016. Precision medicine: Drowning in a regulatory soup? Journal of Law and the Biosciences, v. 3
Doi: http://doi.org/10.1093/jlb/lsw018
2015
Liddicoat, JE., 2015. Reluctance Realised? Emerging Problems with S 117(2)(b) of the Patents Act 1990 (Cth)
Liddicoat, J., Whitton, T. and Nicol, D., 2015. Are the gene-patent storm clouds dissipating? A global snapshot. Nat Biotechnol, v. 33
Doi: http://doi.org/10.1038/nbt.3182
2014
Liddicoat, JE., 2014. Re-Evaluating Innocent Infringement in Australia: Patent Numbers and Virtual Marking
Nicol, D., Hagger, M., Ries, N. and Liddicoat, J., 2014. Time to Get Serious about Privacy Policies: The Special Case of Genetic Privacy Federal Law Review, v. 42
Doi: 10.22145/flr.42.1.7
Nielsen, JL., Nicol, D. and Liddicoat, JE., 2014. Sharing the Burden in Australian Drug Discovery and Development: Collaborative Trends in Translational Research
Liddicoat, JE. and Nicol, D., 2014. Re-Evaluating False Patent Marking in Australia
Nielsen, JL., Nicol, D., Liddicoat, JE. and Whitton, T., 2014. Another Missed Opportunity to Reform Compulsory Licensing and Crown Use in Australia Australian Intellectual Property Journal,
2013 (Published online)
Nicol, D., Liddicoat, J. and Critchley, C., 2013 (Published online). A Role for Virtual Biotechnology Companies in Drug Discovery and Development? Journal of Commercial Biotechnology, v. 19
Doi: 10.5912/jcb611
2013
Nicol, D. and Liddicoat, J., 2013. Do patents impede the provision of genetic tests in Australia? Aust Health Rev, v. 37
Doi: http://doi.org/10.1071/AH13029
2012
Nicol, D. and Liddicoat, JE., 2012. Legislating to Exclude Gene Patents: Difficult and Unhelpful, or Useful and Feasible?
